122 related articles for article (PubMed ID: 27151123)
1. Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
Stern R; Hametner S; Ramona AZ; Moser S; Karpi A; Laferl H; Stauber RE; Zoller HM; Maieron A; Vogel W; Graziadei I; Gschwantler M; Kozbial K; Freissmuth C; Hofer H; Ferenci P
Am J Gastroenterol; 2016 May; 111(5):744-5. PubMed ID: 27151123
[No Abstract] [Full Text] [Related]
2. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
3. A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.
Pérez-Pitarch A; Guglieri-López B; Ferriols-Lisart R; Merino-Sanjuán M
Int J Antimicrob Agents; 2016 Mar; 47(3):184-94. PubMed ID: 26915476
[TBL] [Abstract][Full Text] [Related]
4. Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
Liu CH; Chen YS; Wang SS; Liu CJ; Su TH; Yang HC; Hong CM; Chen PJ; Chen DS; Kao JH
Clin Infect Dis; 2018 Jan; 66(2):289-292. PubMed ID: 29020359
[TBL] [Abstract][Full Text] [Related]
5. The elderly and direct antiviral agents: Constraint or challenge?
Fabrizio C; Saracino A; Scudeller L; Milano E; Dell'Acqua R; Bruno G; Lo Caputo S; Monno L; Milella M; Angarano G
Dig Liver Dis; 2017 Sep; 49(9):1036-1042. PubMed ID: 28651903
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
Torres HA; Economides MP; Angelidakis G; Hosry J; Kyvernitakis A; Mahale P; Jiang Y; Miller E; Blechacz B; Naing A; Samaniego F; Kaseb A; Raad II; Granwehr BP
Am J Gastroenterol; 2019 Feb; 114(2):250-257. PubMed ID: 30410039
[TBL] [Abstract][Full Text] [Related]
7. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
[TBL] [Abstract][Full Text] [Related]
8. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
Werner CR; Schwarz JM; Egetemeyr DP; Beck R; Malek NP; Lauer UM; Berg CP
World J Gastroenterol; 2016 Sep; 22(35):8050-9. PubMed ID: 27672299
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B reactivation in a chronic hepatitis C patient treated with ledipasvir and sofosbuvir: A case report.
Ou P; Fang Z; Chen J
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e17-e18. PubMed ID: 27601170
[No Abstract] [Full Text] [Related]
10. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ
Clin Infect Dis; 2016 Dec; 63(11):1405-1411. PubMed ID: 27553375
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus genotype 4: Genotype 1's little brother.
Llaneras J; Riveiro-Barciela M; Buti M; Esteban R
J Viral Hepat; 2017 Jan; 24(1):4-12. PubMed ID: 27905173
[TBL] [Abstract][Full Text] [Related]
12. Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
Gerber L; Estep M; Stepanova M; Escheik C; Weinstein A; Younossi ZM
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):156-64.e3. PubMed ID: 26241510
[TBL] [Abstract][Full Text] [Related]
13. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C.
Garcia-Pajares F; Tejedor-Tejada J; Torres-Yuste R; Almohalla-Alvárez C; Sánchez-Ocaña R; Peñas-Herrero I; Cimavilla-Román M; de Benito-Sanz M; Sánchez-Martín F; Sánchez-Antolín G
Transplant Proc; 2019; 51(1):74-76. PubMed ID: 30655151
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
16. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.
Walsh CE; Workowski K; Terrault NA; Sax PE; Cohen A; Bowlus CL; Kim AY; Hyland RH; Han B; Wang J; Stamm LM; Brainard DM; McHutchison JG; von Drygalski A; Rhame F; Fried MW; Kouides P; Balba G; Reddy KR
Haemophilia; 2017 Mar; 23(2):198-206. PubMed ID: 28124511
[TBL] [Abstract][Full Text] [Related]
17. Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case.
Spooner LM; Abraham GM
Am J Health Syst Pharm; 2017 Apr; 74(8):555. PubMed ID: 28389452
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
19. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Beinhardt S; Al Zoairy R; Ferenci P; Kozbial K; Freissmuth C; Stern R; Stättermayer AF; Stauber R; Strasser M; Zoller H; Watschinger B; Schmidt A; Trauner M; Hofer H; Maieron A
Transpl Int; 2016 Sep; 29(9):999-1007. PubMed ID: 27203857
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
